BioCryst Pharmaceuticals (BCRX) to Present Three Posters on BCX4208 as Gout Treatment
Tweet Send to a Friend
BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) announced that additional safety and efficacy results from its BCX4208 gout program ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
